Molecular Pathology of Cancer Group

Search for publications

Only original articles, editorials, guidelines.

  • González-Martín A, Rubio MJ, Heitz F, Depont Christensen R, Colombo N, Van Gorp T, Romeo M, Ray-Coquard I, Gaba L, Leary A, De Sande LM, Lebreton C, Redondo A, Fabbro M, Barretina Ginesta MP, Follana P, Pérez-Fidalgo JA, Rodrigues M, Santaballa A, Sabatier R, Bermejo-Pérez MJ, Lotz JP, Pardo B, Marquina G, Sánchez-Lorenzo L, Quindós M, Estévez-García P, Guerra Alía E, Manso L, Casado V, Kommoss S, Tognon G, Henry S, Bruchim I, Oaknin A, Selle F.

    Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.

    JOURNAL OF CLINICAL ONCOLOGY . 42(36): 4294-4304.

    [doi:10.1200/JCO.24.00668]

  • Berges-Gimeno MP, Barra-Castro A, Fernandez-Lozano C, Solano-Solares E, Martinez-Jañez N, Pueyo-Lopez C, Martínez-Botas J.

    Two Nonimmediate Reactions to Oxaliplatin and Docetaxel Confirmed by Lymphocyte Transformation Test and Treated With Successful Rapid Desensitization Procedures.

    Journal of investigational allergology & clinical immunology . : 0-0.

    [doi:10.18176/jiaci.1030]

  • Bonura GF, Biancheri P, Rainer J, Soriani P, Rodriguez de Santiago E, Parrella A, Campioli A, Guerra E, Gualdi E, Pignatti A, Manno M.

    Spinal anesthesia for endoscopic submucosal dissection of large rectosigmoid lesions: Feasibility study.

    Endoscopy International Open . 12(12): 1447-1452.

    [doi:10.1055/a-2441-2543]

  • Kime A, Bataillon G, Treilleux I, Callens C, Selle F, Heitz F, Cinieri S, González-Martin A, Schauer C, Lindahl G, Parma G, Vergote I, Matsumoto T, Blonz C, Canzler U, Mosconi AM, Guerra Alía EM, Pujade-Lauraine E, Genestie C, Ray-Coquard I, Just PA.

    Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma?

    Archives of pathology & laboratory medicine . : .

    [doi:10.5858/arpa.2024-0081-OA]

  • Garcia-Donas, Jesus, Garrigos, Laia, Lainez, Nuria, Santaballa, Ana, Redondo, Andres, Cueva, Juan Fernando, Rubio, M. Jesus, Prieto, Mario, Lopez-Guerrero, Jose Antonio, Garcia-Casado, Zaida, Barquin, Aranzanzu, Grande, Enrique, Alia, Eva Guerra, Sevillano, Elena, Bover, Isabel, Grazioso, Tatiana P., Sanchez-Escribano, Ramon, Hurtado, Alicia, Navarro, Paloma, Rodriguez-Moreno, Juan Francisco.

    Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01)

    CLINICAL & TRANSLATIONAL ONCOLOGY . : .

    [doi:10.1007/s12094-024-03827-4]

  • Montégut C, Falandry C, Cinieri S, Cropet C, Montane L, Rousseau F, Joly F, Moubarak M, Mosconi AM, Guerra-Alía EM, Schauer C, Fujiwara H, Vergote I, Parma G, Lindahl G, Anota A, Canzler U, Marmé F, Pujade-Lauraine E, Ray-Coquard I, Sabatier R.

    Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA-1/ENGOT-ov25.

    ONCOLOGIST . : .

    [doi:10.1093/oncolo/oyae322]

  • Cortés A, López-Miranda E, Fernández-Ortega A, Carañana V, Servitja S, Urruticoechea A, Lema-Roso L, Márquez A, Lazaris A, Alcalá-López D, Mina L, Gener P, Rodríguez-Morató J, Antonarelli G, Llombart-Cussac A, Pérez-García J, Cortés J.

    Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study.

    Breast . 78: 103834-103834.

    [doi:10.1016/j.breast.2024.103834]

  • Matias-Guiu X, Lax S, Raspollini MR, Palacios J, Zheng W, Liu C, de Brot L, Lordello L, Hardisson D, Gaffney D, Mutch D, Scambia G, Creutzberg CL, Fotopoulou C, Berek JS, Concin N.

    FIGO 2023 staging for endometrial cancer, when, if it is not now?

    EUROPEAN JOURNAL OF CANCER . 213: 115115-115115.

    [doi:10.1016/j.ejca.2024.115115]

  • Palacios P, Palacios I, Palacios A, Lorente A, Mariscal G, Benlloch M, Palacios J.

    Effect of bariatric surgery on postoperative outcomes of total hip arthroplasty: An updated systematic review and meta-analysis.

    ASIAN JOURNAL OF SURGERY . : .

    [doi:10.1016/j.asjsur.2024.11.003]

  • Cortés-Salgado A, Serrano JJ, Cordero Pereda D, Menacho M, del Rey JM, Del Campo-Albendea L, Saavedra C, Chamorro J, Rosero D, Sotoca P, Guillén-Ponce C, Guerra E, Fernández-Abad M, López-Miranda E, Martínez-Jáñez N, Gion M, Salazar MT, Agudo-Quílez P, Garrido P, Alonso Salinas GL.

    Anthracyclines-induced cardiotoxicity in patients with early breast cancer carrying germline BRCA1/2 mutation: the BRCAN study.

    ONCOLOGIST . : .

    [doi:10.1093/oncolo/oyae299]

  • Quintela-Fandino M, Bermejo B, Zamora E, Moreno F, Garcia-Saenz JÁ, Pernas S, Martinez Jañez N, Jiménez D, Adrover E, Andrés R, Mourón S, Bueno MJ, Manso L, Viñas G, Alba E, Llombart-Cussac A, Cortes J, Tebar C, Roe DJ, Grant A, Watson A, Colomer R, Mouneimne G.

    High mechanical conditioning by tumor extracellular matrix stiffness is a predictive biomarker for anti-fibrotic therapy in HER2-negative breast cancer.

    CLINICAL CANCER RESEARCH . 30(22): 5094-5104.

    [doi:10.1158/1078-0432.CCR-24-1518]

  • Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Alía EM, Matsumoto T, Vergote I, Colombo N, Mäenpää J, Lebreton C, de Gregorio N, Mosconi AM, Rubio-Pérez MJ, Bourgeois H, Fasching PA, Cecere SC, Hardy-Bessard AC, Denschlag D, de Percin S, Hanker L, Favier L, Bauerschlag D, Desauw C, Hillemanns P, Largillier R, Sehouli J, Grenier J, Pujade-Lauraine E, Ray-Coquard I.

    Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.

    Annals of oncology : official journal of the European Society for Medical Oncology . : .

    [doi:10.1016/j.annonc.2024.10.828]

  • Verlingue L, Italiano A, Prenen H, Guerra Alia EM, Tosi D, Perets R, Lugowska I, Moiseyenko V, Gumus M, Arslan C, Lindsay CR, Deva S, Taus Á, Oaknin A, Rottey S, Cicin I, Goksu SS, Smolin A, Roselló-Keränen S, Habigt C, Marbach D, Boetsch C, Dejardin D, Sleiman N, Evers S, Richard M, Ardeshir C, Charo J, Kraxner A, Teichgräber V, Keshelava N, Dziadziuszko R.

    Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma.

    EBioMedicine . 109: 105374-105374. Number of citations: 1

    [doi:10.1016/j.ebiom.2024.105374]

  • Perez-Fidalgo JA, Gálvez-Montosa F, Guerra EM, Madariaga A, Manzano A, Martin-Lorente C, Rubio-Pérez MJ, Alarcón J, Barretina-Ginesta MP, Gaba L.

    SEOM-GEICO clinical guideline on epithelial ovarian cancer (2023).

    CLINICAL & TRANSLATIONAL ONCOLOGY . 26(11): 2758-2770. Number of citations: 2

    [doi:10.1007/s12094-024-03531-3]

  • Alonso-Gordoa T, Jimenez-Fonseca P, Martinez-Trufero J, Navarro M, Porras I, Rubió-Casadevall J, Arregui Valles M, Basté N, Hernando J, Iglesias Docampo L.

    SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023).

    CLINICAL & TRANSLATIONAL ONCOLOGY . 26(11): 2902-2916.

    [doi:10.1007/s12094-024-03736-6]

  • Carretero-Barrio I, Pijuan L, Illarramendi A, Curto D, López-Ríos F, Estébanez-Gallo Á, Castellvi J, Granados-Aparici S, Compañ-Quilis D, Noguera R, Esteban-Rodríguez I, Sánchez-Güerri I, Ramos-Guerra AD, Ortuño JE, Garrido P, Ledesma-Carbayo MJ, Benito A, Palacios J.

    Concordance in the estimation of tumor percentage in non-small cell lung cancer using digital pathology.

    SCIENTIFIC REPORTS . 14(1): 24163-24163.

    [doi:10.1038/s41598-024-75175-w]

  • Agudo-Quílez P, Martín-Moro F, Antoñana Ugalde S, Blanco-Peláez E, García-Cosío M, Tenelanda A, Lledó Navarro JL, López-Jiménez J, Zamorano Gómez JL.

    Primary Cardiac Aggressive B-Cell Lymphoma Affecting Right Ventricle and Acute Cardiovascular Events: Multidisciplinary Approach.

    Jacc. Case Reports . 29(19): 102562-102562.

    [doi:10.1016/j.jaccas.2024.102562]

  • Guerrero-Zotano Á, Pérez-García JM, Ruiz-Borrego M, Bermejo B, Gil-Gil M, de la Haba J, Alba Conejo E, Quiroga V, Carañana V, Urruticoechea A, Morales S, Bellet M, Antón A, Fernández-Abad M, Sánchez-Rovira P, Calabuig L, Pérez-Escuredo J, Sampayo-Cordero M, Cortés J, Llombart-Cussac A.

    Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score =18: DxCARTES study.

    ESMO open . 9(10): 103733-103733.

    [doi:10.1016/j.esmoop.2024.103733]